Analystreport

Trillium Therapeutics Inc (NASDAQ: TRIL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.

Trillium Therapeutics Inc. - Common Shares  (TRIL) 
Last trillium therapeutics inc. - common shares earnings: 5/13 07:00 am Check Earnings Report